Market Newsdesk

WALTHAM, Mass., May 4, 2021 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax’s management team will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, May 11, to discuss the Company’s financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Conference ID: 8178876
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/4gwngoxq

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website, www.syndax.com.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
[email protected]
Tel 212.600.1902

Media Contact
Benjamin Kolinski
GCI Health
[email protected]
Tel 862.368.4464

SNDX-G

 

View original content:http://www.prnewswire.com/news-releases/syndax-to-announce-first-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-may-11-2021-301282838.html

SOURCE Syndax Pharmaceuticals, Inc.

HOUSTON, May 4, 2021 /PRNewswire/ — Main Street Capital Corporation (NYSE: MAIN) (“Main Street”) is pleased to announce that its Board of Directors declared regular monthly cash dividends of $0.205 per share for each of July, August and September 2021.  These monthly dividends, which will be payable pursuant to the table below, total $0.615 per share for the third quarter of 2021, which are consistent with the regular monthly dividends declared for the second quarter of 2021 and the third quarter of 2020. Since its October 2007 initial public offering, Main Street has periodically increased the amount of its regular monthly dividends paid per share and has never reduced its regular monthly dividend amount per share.  Including all dividends declared to date, Main Street will have paid $31.45 per share in cumulative cash dividends since its October 2007 initial public offering at $15.00 per share. 

The final determination of the tax attributes for dividends each year are made after the close of the tax year.  The final tax attributes for 2021 dividends are currently expected to include a combination of ordinary taxable income and qualified dividends and may include capital gains and return of capital.

Main Street maintains a dividend reinvestment and direct stock purchase plan (the “Plan”).  The dividend reinvestment feature of the Plan (the “DRIP”) provides for the reinvestment of dividends on behalf of Main Street’s registered stockholders who hold their shares with Main Street’s transfer agent and registrar, American Stock Transfer and Trust Company, or certain brokerage firms that have elected to participate in the DRIP.  Under the DRIP, if Main Street declares a dividend, registered stockholders who have not “opted out” of the DRIP by the dividend record date will have their dividend automatically reinvested into additional shares of Main Street common stock.  The direct stock purchase feature of the Plan (the “DSPP”) provides investors with a convenient and economical method to purchase shares of Main Street common stock.  More information about the Plan (including the DSPP prospectus) can be found on the Main Street website (https://ir.mainstcapital.com/dividend-reinvestment-and-direct-stock-purchase-plan). 

ABOUT MAIN STREET CAPITAL CORPORATION
Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides long-term debt and equity capital to lower middle market companies and debt capital to middle market companies.  Main Street’s portfolio investments are typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors.  Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides “one stop” financing alternatives within its lower middle market portfolio.  Main Street’s lower middle market companies generally have annual revenues between $10 million and $150 million.  Main Street’s middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies.

Main Street, through its wholly owned portfolio company MSC Adviser I, LLC (“MSC Adviser”), also maintains an asset management business through which it manages investments for external parties.  MSC Adviser is registered as an investment adviser under the Investment Advisers Act of 1940.     

FORWARD-LOOKING STATEMENTS
This press release may contain certain forward-looking statements, including but not limited to the continued payment and growth of future dividends and the potential tax attributes for 2021 dividends.  Any such statements other than statements of historical fact are likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under Main Street’s control, and that Main Street may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance.  Actual performance and results could vary materially from these estimates and projections of the future as a result of a number of factors, including those described from time to time in Main Street’s filings with the Securities and Exchange Commission.  Such statements speak only as of the time when made and are based on information available to Main Street as of the date hereof and are qualified in their entirety by this cautionary statement.  Main Street assumes no obligation to revise or update any such statement now or in the future.

Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, CEO, [email protected]
Brent D. Smith, CFO, [email protected]                
713-350-6000

Dennard Lascar Investor Relations

Ken Dennard | [email protected]  
Zach Vaughan | [email protected]   
713-529-6600

 

 

View original content:http://www.prnewswire.com/news-releases/main-street-announces-third-quarter-2021-regular-monthly-dividends-301282578.html

SOURCE Main Street Capital Corporation

TEL AVIV, Israel, May 4, 2021 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive top-line results from the Company’s GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, in combination with granulocyte colony stimulating factor (G-CSF, the standard of care in this indication), for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.

An analysis of data on all 122 enrolled patients (the intent to treat, or ITT, population) found highly statistically significant evidence across all primary and secondary endpoints favoring Motixafortide in addition to G-CSF, as compared to placebo plus G-CSF. In addition, the combination was found to be safe and well tolerated.

The primary endpoint of the study demonstrated a 4.9-fold increase (70.0% vs 14.3%; difference 54.6%; 95% CI 39.7-69.5%; p<0.0001) in the proportion of patients in the treatment arm, as compared to the control arm mobilizing ≥ 6 million CD34+ cells/kg in up to two apheresis sessions, and after only one administration of Motixafortide. This translates to an odds-ratio of 12.9.

The study also achieved its main secondary endpoint, demonstrating a 14.1-fold increase (67.5% vs 4.8%; difference 61.7%; 95% CI 49.5-73.8%; p<0.0001) in the proportion of patients in the treatment arm, as compared to the control arm, who mobilized ≥ 6 million CD34+ cells/kg in just one apheresis session. This translates to an odds-ratio of 56.0.

Other important data from the study include median number of CD34+ cells collected on the first day of apheresis (8.5 million in the treatment arm vs 1.5 million in the control arm) – a 5.6-fold increase. The addition of Motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session, compared to 10.8% in the G-CSF arm – an 8.2-fold increase. Engraftment endpoints, including the number of days needed for engraftment, success of engraftment and the durability of engraftment 100 days post-transplant, further support the study’s success.

“The results of the GENESIS study are extremely impressive, and all the more so when considering that almost 90% of the patients in the treatment arm proceeded to transplantation after only one apheresis session,” stated John DiPersio, MD, Washington University School of Medicine, and lead investigator of the study. “This is a great achievement in alleviating the burden for the patients and reducing hospital resources. I believe these results make the combination of Motixafortide and G-CSF a very attractive candidate for use in all patients with multiple myeloma undergoing autologous stem-cell transplantation.”

“These strikingly positive data significantly exceeded our expectations, and are truly transformational for our company,” stated Philip Serlin, Chief Executive Officer of BioLineRx. “The statistical significance across all primary and secondary endpoints was consistent across twelve different sensitivity analyses. These results support our goal of becoming the standard of care for autologous bone-marrow transplantation, providing a strong clinical and pharmaco-economic advantage for its use, on top of G-CSF, in all transplant procedures.  

“We are working aggressively to gain regulatory approval for Motixafortide in this transplant setting for multiple myeloma patients – with plans to make an NDA submission in the first half of next year – and we are also pressing forward to unlock the full potential of this therapy in this and other stem-cell mobilization indications. I would like to express our sincere thanks to the patients and investigators who participated in the study and enabled its great success,” Mr. Serlin concluded.

Conference Call and Webcast Information
BioLineRx will hold a conference call today, Tuesday, May 4, 2021 at 10:00 a.m. EDT. To access the conference call, please dial +1-866-860-9642 from the US or +972-3-918-0644 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available for a limited time approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until May 6, 2021; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About the GENESIS Trial
The GENESIS trial (NCT03246529) was initiated in December 2017. GENESIS was a randomized, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of Motixafortide and G-CSF, compared to placebo and G-CSF, for the mobilization of hematopoietic stem-cells for autologous transplantation in multiple myeloma patients. The primary objective of the study was to demonstrate that only one dose of Motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize ≥ 6 million CD34+ cells in up to two apheresis sessions. Additional objectives included time to engraftment of neutrophils and platelets and durability of engraftment, as well as other efficacy and safety parameters. Local laboratories and a central laboratory were used to determine CD34+ cell yields. For regulatory purposes, efficacy endpoints were calculated using the percentage of CD34+ cells determined by the central laboratory. The local laboratory values were used for all clinical decisions, including the number of apheresis days and the decision to proceed to transplantation.

About
BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company’s lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem-cell mobilization for autologous bone-marrow transplantation. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA^® and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all rights to Motixafortide), and is currently being studied in combination with LIBTAYO^® and chemotherapy as a first-line PDAC therapy.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company’s website at www.biolinerx.com, where you can review the Company’s SEC filings, press releases, announcements and events.

Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx’s preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx’s therapeutic candidates; BioLineRx’s ability to establish and maintain corporate collaborations; BioLineRx’s ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx’s therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx’s business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx’s expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx’s industry; risks related to the COVID-19 pandemic; and statements as to the impact of the political and security situation in Israel on BioLineRx’s business. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on February 23, 2021. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthy

LifeSci Advisors, LLC
+1-212-915-2564
[email protected]

or

Moran Meir

LifeSci Advisors, LLC
+972-54-476-4945
[email protected]

View original content:http://www.prnewswire.com/news-releases/biolinerx-announces-positive-top-line-results-from-genesis-phase-3-trial-of-motixafortide-in-stem-cell-mobilization-for-autologous-bone-marrow-transplantation-in-multiple-myeloma-patients-301282969.html

SOURCE BioLineRx Ltd.

TEL AVIV, Israel and HOUSTON, May 4, 2021 /PRNewswire/ — Arbe, a global leader in next-generation 4D Imaging Radar Solutions, today announced its leading 4D Imaging Radar Solution with 2K resolution is now available on the open NVIDIA DRIVE platform.

Arbe’s imaging radar availability aims to accelerate the development of autonomous vehicles. By allowing leading OEMs and Tier 1 suppliers to access the 4D imaging radar data on NVIDIA’s AV platform, Arbe’s solution can serve as the basis for advanced safety applications, sensor fusion, and perception algorithm development.

NVIDIA DRIVE is a scalable, software-defined, end-to-end AI platform for the transportation industry, delivering the computing horsepower and software necessary for highly automated and autonomous driving. Hundreds of companies around the world are developing on NVIDIA DRIVE, including auto- and truck makers, Tier 1 suppliers, robotaxis, sensor and mapping companies and AV startups.

Arbe has developed the world’s first radar to separate, track, and identify objects in 2K ultra-high resolution in both azimuth and elevation via a proprietary chipset with the highest channel count in the industry and a dedicated radar processor. Arbe’s solution provides detection of stationary and moving objects in any weather or lighting condition, providing safety to pedestrians, cyclists, and others, while also eliminating false alarms. The 4D Imaging Radar Solution also provides advanced long-range perception capabilities with a wide field of view.

“We are excited to be part of NVIDIA’s ecosystem of partners — providing access to our 4D Imaging Radar to the world’s most forward-thinking automakers developing on NVIDIA DRIVE,” says Ram Machness, Chief Business Officer of Arbe. “The availability of Arbe on NVIDIA’s platform will expedite the development of safety features for ADAS applications and autonomous vehicles, and provide a platform for sensor fusion development.”

“OEMs and Tier-1 suppliers will now benefit from Arbe’s 4D Imaging Radar solution as part of the NVIDIA DRIVE ecosystem,” says Rammy Bahalul, director of autonomous machines and vehicles at NVIDIA. “With Arbe’s advanced sensing, our customers have access to enhanced levels of safety and paradigm-changing perception algorithms for their vehicles.”

Arbe recently revealed plans to go public through a SPAC merger with Industrial Tech Acquisitions, Inc (NASDAQ: ITAC). 

About
Arbe Robotics, Ltd.

Arbe, a global leader in next-generation 4D Imaging Radar Chipset Solutions, is spearheading a radar revolution, enabling truly safe driver-assist systems today while paving the way to full autonomous-driving. Empowering automakers, tier-1 automotive suppliers, autonomous ground vehicles, commercial and industrial vehicles, and a wide array of safety applications with advanced sensing and paradigm-changing perception. Arbe’s imaging radar is 100 times more detailed than any other radar on the market and is a mandatory sensor for L2+ and higher autonomy. Arbe is a leader in the fast-growing automotive radar market that has an estimated total addressable market of $11 billion in 2025. Arbe is based in Tel Aviv, Israel, and has offices in the United States.

On March 18, 2021, Arbe announced that it had entered into, among other things, a definitive business combination agreement with Industrial Tech Acquisitions, Inc. (NASDAQ: ITAC), a publicly traded special purpose acquisition company (“ITAC”). Subject to the satisfaction of the terms and conditions set forth in the business combination agreement, upon closing of the transactions, the combined company will operate under the “Arbe Robotics Ltd.” name and is expected to be listed on Nasdaq under the new ticker symbol “ARBE”.

About
 Industrial Tech Acquisitions, Inc (“ITAC”)

ITAC is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. ITAC is sponsored by Texas Ventures, a leading technology and venture capital firm with expertise in capital markets and structured finance. The firm provides guidance, insight and capital to assist entrepreneurs and managers who have the desire and talent to build exceptional companies. The Texas Ventures’ approach is to identify emerging trends and opportunities prior to recognition by the broader marketplace, and to take a proactive approach in working with entrepreneurs and managers who have the determination to build world-class companies.

Important
 Notice Regarding Forward-Looking Statements 

This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Arbe and NVIDIA and the transactions contemplated hereunder, and the parties’ perspectives and expectations, are forward looking statements. Such statements include, but are not limited to, statements regarding the proposed partnership between Arbe and NVIDIA , expected growth opportunities for Arbe, anticipated future financial and operating performance and results attributable therefrom, and the expected timing of the implementation of the partnership. The words “expect,” “believe,” “estimate,” “intend,” “plan”, “anticipate”, “project”, “may”, “should”, “potential” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.

Such risks and uncertainties include, but are not limited to, risks related to: (i) the expected timing and likelihood of the generation of revenue from the NVIDIA DRIVE platform; (ii) the occurrence of any event, change or other circumstances that could affect Arbe’s use of the NVIDIA DRIVE platform; (iii) costs related to the making Arbe’s products accessible through the NVIDIA DRIVE platform; (iv) the occurrence of a material adverse change with respect to the financial position, performance, operations or prospects of  Arbe or NVIDIA ; (v) the disruption of Arbe management time from ongoing business operations or performance of the units to be sold through the NVIDIA DRIVE platform; (vi) changes in applicable laws or regulations, including laws and regulations affecting the market for Arbe’s products; (vii) the possibility that Arbe may be adversely affected by other economic, business, and/or competitive factors, or the continuing effects of the COVID-19 pandemic, the worsening thereof or other future pandemics; (viii) risks related to the matters set forth in the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies, issued by the Division of Corporate Finance of the SEC on April 12, 2021 and costs related to such matters, and (ix) other risks and uncertainties, including those to be identified in the proxy statement/prospectus (when available) relating to the proposed business combination between ITAC and Arbe, including those under “Risk Factors,” “Cautionary Notes Concerning Forward-Looking Statements” and “Arbe Management’s and Analysis of Financial Conditions and Results of Operations” therein, and in other filings with the Securities and Exchange Commission (“SEC”) by ITAC or Arbe. Arbe cautions that the foregoing list of factors is not exclusive. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and Arbe undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

ADDITIONAL INFORMATION

General

Arbe intends to file with the Securities and Exchange Commission (the “SEC“) a Registration Statement on Form F-4 (as amended, the “Registration Statement“), which will include a preliminary proxy statement of Industrial Tech Acquisitions, Inc., a Delaware corporation (“ITAC“), and a prospectus in connection with the proposed business combination (the “Transaction“) involving Arbe, ITAC and Autobot MergerSub, Inc., a Delaware corporation and a wholly owned subsidiary of Arbe (“Merger Sub“). The definitive proxy statement and other relevant documents will be mailed to stockholders of ITAC as of a record date to be established for voting on the Transaction and related matters. Stockholders of ITAC and other interested persons are advised to read, when available, the preliminary proxy statement, and amendments thereto, and the definitive proxy statement in connection with ITAC’s solicitation of proxies for the special meeting of its stockholders to be held to approve the Transaction and related matters because these documents will contain important information about ITAC, Arbe, Merger Sub and the Transaction. Stockholders of ITAC will also be able to obtain copies of the Registration Statement and the proxy statement/prospectus, without charge, once available, on the SEC’s website at www.sec.gov or by directing a request to ITAC by contacting E. Scott Crist, Chief Executive Officer, c/o Industrial Tech Acquisitions, Inc., 5090 Richmond Avenue, Suite 319, Houston, Texas 77056, at (713) 599-1300 or at [email protected].

Participants in the Solicitation

ITAC, Arbe and certain of their respective directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from the shareholders of ITAC in favor of the approval of the Transaction. Stockholders of ITAC and other interested persons may obtain more information regarding the names and interests in the Transaction of ITAC’s directors and officers in ITAC’s filings with the SEC. Additional information regarding the interests of such potential participants will also be included in the Registration Statement and other relevant documents when they are filed with the SEC. Free copies of these documents may be obtained at the SEC’s website, https://www.sec.gov/edgar/searchedgar/companysearch.html, or as provided in the preceding paragraph.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/arbe-announces-availability-of-4d-imaging-radar-solution-on-nvidia-drive-platform-301282962.html

SOURCE Arbe

NEW YORK, May 4, 2021 /PRNewswire/ — Shutterstock, Inc. (NYSE: SSTK), a leading global creative platform offering full-service solutions, high-quality content, and tools for brands, businesses and media companies, together with A+E Networks®, a global multi-platform content company, today announced an exclusive editorial archival footage partnership to represent The A+E Networks® Archive, featuring some of the most popular and culturally-relevant brands in media, including The HISTORY® Channel, A&E®, Lifetime®, and more.

The A+E Networks Footage Archive provides unparalleled access to an unrivaled key collection. From stunning nature visuals, to iconic military and war reenactments, as well as new-to-market, pre-cleared assets for commercial projects, this remarkable footage archive will enable storytelling opportunities across multiple verticals for producers, publishers and documentary filmmakers. This exclusive archival footage collection will form part of Shutterstock Editorial Video which launched in October 2020. With access to over 300,000 clips, Editorial Video has best-in-quality video content, featuring premium live and archival clips across News, Entertainment, Fashion and UGC. 

“Shutterstock is in an exciting period of transformation, as a trusted creative and distribution partner to the world’s brands, agencies, production companies and media,” said Candice Murray, VP of Editorial at Shutterstock. “The archive of A+E Networks® is an exceptional curation of imagery, footage, b-roll and CGI content, and we are thrilled to showcase this unique collection for visual storytelling that will captivate and resonate with audiences globally.”

“As one of the most innovative storytelling companies in the world, A+E Networks® engages worldwide audiences across multiple platforms through its portfolio of media brands, including The HISTORY® Channel, A&E® and Lifetime®,” said Mark Garner, Executive Vice President of Global Content Sales and Business Development, A+E Networks®. “We are excited to partner with Shutterstock, a powerful creative platform with tremendous global reach. Never before have we provided this level of unparalleled access to our archives, one of the most unique footage libraries in existence.”

Visit Editorial Video to access The A+E Networks® Archive.

ABOUT SHUTTERSTOCK

Shutterstock, Inc. (NYSE: SSTK), is a leading global creative platform offering full-service solutions, high-quality content, and tools for brands, businesses and media companies. Directly and through its group subsidiaries, Shutterstock’s comprehensive collection includes high-quality licensed photographs, vectors, illustrations, 3D models, videos and music. Working with its growing community of over 1.7 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 370 million images and more than 21 million video clips available.

Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The Company also owns Bigstock, a value-oriented stock media offering; Shutterstock Studios, an end-to-end custom creative shop; Offset, a high-end image collection; PremiumBeat, a curated royalty-free music library; Shutterstock Editorial, a premier source of editorial images and videos for the world’s media; Amper Music, an AI-driven music platform; and TurboSquid, a leading 3D content marketplace.

For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook.

ABOUT A+E NETWORKS®

A+E Networks^® is a global content company comprised of some of the most popular and culturally-relevant brands in media including A&E^®, Lifetime^®, The HISTORY Channel^®, LMN^®, FYI^®, VICE TV^® and Blaze^®.  A+E Networks’ portfolio extends across platforms and genres, with a scripted production division, A+E Studios™; unscripted production through Six West Media™; independent film unit A&E IndieFilms^®; watch apps, games, FAST channels, AVOD, and SVOD initiatives including Lifetime Movie Club and HISTORY Vault; and podcasts such as History This Week, through A+E Digital®;  Experiential/branded live events and Ecommerce through A+E Consumer Enterprises^®; and branded channels, content distribution and scripted/unscripted co-productions around the world through A+E International^®.  A+E Networks’ channels and branded programming reach more than 335 million households in over 200 territories in 41 languages. A+E Networks is a joint venture of Disney-ABC Television Group and Hearst. Follow us on Twitter at twitter.com/aenetworks and Facebook at facebook.com/AENetworks.

View original content to download multimedia:http://www.prnewswire.com/news-releases/shutterstock-editorial-partners-with-ae-networks-for-distribution-of-the-ae-networks-footage-archive-301282730.html

SOURCE Shutterstock, Inc.

MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products, will pair its Maurice icIEF separation instrument with 908 Devices ZipChip device to deliver a seamless workflow for deeper protein characterization. Maurice and the iCE technology are the gold standard in protein characterization, providing absorbance and native fluorescence icIEF detection as well as CE-SDS, saving significant development time and reducing the time to commercialization. 

908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, enables high-resolution separation and mass spec sample introduction with its plug-and-play open access platform ZipChip, which directly integrates electrospray ionization with mass spectrometry. The ZipChip integrates with Thermo Fisher, Sciex, and Bruker mass spectrometers and leverages Capillary Electrophoresis (CE) and electrospray ionization technology in order to minimize sample prep burden, perform high-resolution separations and directly introduce samples into a mass spec instrument. 

Maurice paired with 908 Devices ZipChip allows in-depth characterization of biotherapeutics on an intact and near-native level. This workflow solution will increase scientists’ drug development efficiency through additional rapid, high-resolution separation techniques coupled with mass spectrometry identification.

“We are very excited to collaborate with 908 Devices to provide an integrated workflow that enables fraction analysis for our Maurice users. Analyzing protein charge isoforms is a critical requirement and this enhanced capability using Maurice with the ZipChip and MS will provide a deeper understanding of a molecule through the various stages of development,” stated Dave Eansor, President of Bio-Techne’s Protein Sciences Segment. “Our iCE technology has been the gold standard in protein charge characterization for more than 20 years and this collaboration will provide additional value to the iCE community.”

“By partnering with Bio-Techne and leveraging their market leading Maurice icIEF platform with our ZipChip device, we are together extending the workflow for customers conducting detailed protein characterization of charge variants,” said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. “This collaboration helps advance our reach into the biopharmaceutical market.”

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,500 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

Investor Relations Contact:

David Clair, Senior Director, Investor Relations and Corporate Development
[email protected]
612-656-4416 

About 908 Devices
908 Devices (NASDAQ:MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning. 

908 Devices Contacts 
Emily Fang
PAN Communications for 908 Devices
[email protected] 

Carrie Mendivil, [email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-and-908-devices-announce-joint-collaboration-301281096.html

SOURCE Bio-Techne Corporation

ENGLEWOOD, Colo., May 4, 2021 /PRNewswire/ — Nearly three out of 10 Americans lost their health insurance in 2020¹, and half of those remain uninsured today. Following the pandemic, two-thirds of Americans say they are concerned about their ability to pay medical expenses in 2021². Boost Mobile, which serves millions of underinsured and uninsured customers, today announced it will become the first wireless provider to offer free health care services to its subscribers and their families by partnering with K Health.

As part of Boost Mobile’s Unlimited Plus plan, new subscribers will receive free, 24/7 access to health services via the K Health app straight from their Boost Mobile phone. This new partnership will deliver free access to remote health care services for Boost Mobile customers and their immediate families. Specifically, this will include the opportunity to chat with a doctor directly from a mobile phone; use K Health’s AI-powered symptom checker to understand what is wrong and decide what to do next; and get treatment, including medications prescribed. K Health treats hundreds of adult and pediatric conditions remotely, and also offers personalized treatment plans, such as for anxiety and depression.

While the use of telemedicine has skyrocketed during the pandemic, access to care remains a significant barrier for many Americans, especially those underinsured or uninsured. Boost Mobile’s partnership with K Health will provide real health value to those needing it most.

“Boost Mobile customers are disproportionately affected by rising health care costs. Boost Mobile is bridging the gap by providing affordable wireless access, and now we want to expand those efforts to address the health care divide,” said Stephen Stokols, who heads Boost Mobile. “K Health is the perfect partner to create a pathway to better health for individuals and families who do not have affordable access to medical services, which we estimate is up to half of our user base.”

“Boost Mobile truly prioritizes its customers and is creating solutions to meet their needs,” said Ran Shaul, chief product officer and co-founder of K Health. “Our partnership brings together Boost Mobile’s innovation with K’s unique combination of shared knowledge, made possible by AI, and our fleet of world-class clinicians to offer 24/7 access to the best high-quality medicine — all from a smartphone.”

K Health will be available for free to new Unlimited Plus subscribers, and for a discounted service fee of $7.99 per month for other Boost Mobile service plans. Boost Mobile customers will be able to take advantage of K Health’s data-driven primary care system with over four million users on its platform. Boost Mobile users can sign up at boostmobile.com/health to be first in line for the official launch early this summer.

For more information about K Health, please visit www.khealth.com.

About Boost Mobile


Boost Mobile
 provides award-winning, best-in-class value and connectivity to U.S. wireless consumers through access to the carrier’s Expanded Data Network and competitive consumer plans with no annual service contracts. In 2020, DISH became a nationwide U.S. wireless carrier through the acquisition of Boost Mobile. DISH continues to innovate in wireless, building the nation’s first virtualized, standalone 5G broadband network. DISH Wireless L.L.C. operates Boost Mobile. DISH Wireless L.L.C. is a subsidiary of DISH Network Corporation (NASDAQ: DISH), a Fortune 250 company. Learn more about Boost Mobile online on Facebook, Instagram, Twitter and YouTube.

¹
 According to ValuePenguin.com Health Care Survey
² According to AccessOne Health Care Survey

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/boost-mobile-to-become-first-wireless-carrier-to-offer-free-health-care-services-301282855.html

SOURCE Boost Mobile

CHICAGO, May 4, 2021 /PRNewswire/ — Cars.com (NYSE: CARS), a leading digital marketplace and solutions provider for the automotive industry, announced today that an astounding 10 million car buyers have left reviews for local dealers on its platform, powered by its DealerRater technology.¹ For years, Cars.com has provided a venue for consumers to voice their honest feedback about local car dealers, vehicles and even individual salespeople, making it the broadest and largest automotive review platform.

The 10 million milestone comes as digital-first experiences take center stage and consumers are increasingly seeking out reviews about how local businesses are handling health and safety concerns related to the pandemic. In fact, 38% of consumers report that they read more reviews because of COVID-19.² The number of people leaving reviews about local dealers is also on the rise: March 2021 marked the highest volume ever of new reviews on the Cars.com platform, with nearly 140,000 reviews posted in a single month.¹

“Cars are a large, considered purchase, and consumers can spend months researching about what and where to buy. Reviews have been and will continue to be critical to the research phase as shoppers trust unbiased advice from others like them,” said Brooke Skinner Ricketts, chief experience officer at Cars.com. “Reviews on Cars.com have become even more important over the last year as consumers pay closer attention to the buying experience offered by local businesses as consumers seek the best overall experience for their needs.”

Consumers have rewarded local car dealerships for their recent efforts, leaving 90% positive reviews during the pandemic’s peak.³ Other national trends from recent Cars.com and DealerRater research include:

• Three-star minimum for most purchases. One in 3 shoppers won’t make a purchase without reading a review.^²  The majority of shoppers (68%) state they will not buy from a business with fewer than three stars.^²
• The rise of “no touch” retail. Reviews mentioning contactless services, including “safe pickup” and “home delivery,” rose 1,100% in just the past year,^³  highlighting how car dealers are meeting the changing needs of shoppers and transforming the car-buying process.
• Health and safety: new and influential review criteria. Sixty-nine percent of respondents wouldn’t buy from a business with poor or negative reviews about pandemic health and safety measures.^²
• Reviews drive sales. Over 85% of dealerships report DealerRater reviews have helped them sell and/or service more vehicles.^⁴
• Employee reviews spur requests, referrals and sales. Almost 80% of DealerRater users said consumers have specifically asked for them because of their online reviews and reputation. Nearly 90% of shopper requests to work with a specific sales representative led to a sale.⁴ 

To learn more about Cars.com and read reviews about local dealerships, visit www.Cars.com.
To learn more about DealerRater technology, visit www.dealerrater.com.

¹

Cars.com and DealerRater Internal Data, Volume of Dealership Reviews, April 2021


²

DealerRater Consumer Survey April 21-23, 2021; 1,036 respondents


³

Internal Data, Cars.com and DealerRater platform looking at ~1 million reviews submitted between March 2020 and March 2021


⁴

DealerRater Dealer Survey March 2021, 985 respondents

ABOUT CARS.COM INC.
CARS is a leading digital marketplace and solutions provider for the automotive industry that connects car shoppers with sellers. Launched in 1998 with the flagship marketplace site Cars.com and headquartered in Chicago, the Company empowers shoppers with the data, resources and digital tools needed to make informed buying decisions and seamlessly connect with automotive retailers. In a rapidly changing market, CARS enables dealerships and OEMs with innovative technical solutions and data-driven intelligence to better reach and influence ready-to-buy shoppers, increase inventory turn and gain market share.

In addition to Cars.com, CARS brands include Dealer Inspire, a technology provider building solutions that future-proof dealerships with more efficient operations and connected digital experiences; FUEL, which gives dealers and OEMs the opportunity to harness the untapped power of digital video by leveraging Cars.com’s pure audience of in-market car shoppers, and DealerRater, a leading car dealer review and reputation management platform.

The full suite of CARS brands include Cars.com™, Dealer Inspire®, FUEL™, DealerRater®, Auto.com™, PickupTrucks.com™ and NewCars.com®. For more information, visit www.Cars.com.

ABOUT DEALER RATER

DealerRater, a Cars.com company, is a leading car dealer review and reputation management platform that empowers dealerships to efficiently grow their brands by accelerating, automating and amplifying review generation across digital channels. By offering a product suite that allows qualified dealerships to manage their digital presence and build and maintain their online reputation, DealerRater helps dealers drive new customer connections every day, achieve higher SEO rankings and, ultimately, generate higher-quality leads that close, faster.

Founded in 2002, DealerRater reviews cover 44,000 U.S. and Canadian dealerships, including a network of more than 5,000 Certified Dealers, that reaches an audience of more than 34 million consumers each month.

View original content to download multimedia:http://www.prnewswire.com/news-releases/carscom-reaches-milestone-10-million-dealership-reviews-from-car-buyers-with-recent-growth-spurred-by-the-pandemic-301282722.html

SOURCE Cars.com Inc.

VANCOUVER, BC, May 4, 2021 /PRNewswire/ – Strategic Resources Inc. (TSXV: SR) (the “Company” or “Strategic”) is pleased to announce it has received positive results from the Preliminary Economic Assessment (the “PEA”), prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101”), for its 100%-owned Mustavaara Project (“Mustavaara” or the “Project”). The PEA outlines a long-life economic project in current market conditions.

Scott Hicks, CEO and Director, commented: “I am extremely pleased that we have demonstrated the ability for this brownfield project to come back into production in the future. Management will now turn its focus to engaging with Finnish authorities on the existing permits held by the previous owner that require transferring and extension, key environmental monitoring work and evaluating moving to a pre-feasibility study.”

Preliminary Economic Assessment Summary

The PEA, initiated in late 2020, was produced by a team of independent consultants that possess extensive expertise in their respective fields. Further details on the contributors can be found in the Qualified Persons section of this news release.

All amounts are in Euros unless otherwise specified. Base case economics were calculated using a ferrovanadium (“FeV80”) price of US$32.00 per kilogram and pig iron price of US$450 per tonne. An exchange rate of EUR:USD of 1.18 was used. The effective date of the PEA is May 4, 2021 and a technical report relating to the PEA will be filed on SEDAR within 45 days of this news release.

The PEA’s highlights include the following estimates:

• Life of mine (“LOM”) average annual production of 4.6 kt of FeV80
• LOM average annual co-product production of 329 kt of pig iron
• 20.25-year mine life
• 10,400 tpd processing operation over the life of mine
• After-tax NPV (8%) and IRR of €190 million and 12.2%
• Average all-in sustaining co-product cash costs of €15.2 /kg FeV80 and €210.7/t pig iron
• LOM revenue mix of 46.7 % FeV80, 50.8 % pig iron and 2.6 % other by-products
• Initial capital costs of €597 million
• Life of mine sustaining capital and closure costs of €94 million

The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. Mineral resources are not mineral reserves and do not have demonstrated economic viability. There is no certainty that the PEA will be realized.

Next Steps and Recommendations

The PEA report recommends advancing to a pre-feasibility study on the Project, which would require approximately €1.4M euros and include additional hydrological, comminution, metallurgical and engineering work. Prior to commencing such work, Strategic will engage with local authorities on the existing permits held by the previous owner and assess key environmental monitoring programs.

 

 

 

The NI 43-101 mineral resource estimate summary above is calculated using the base case cut-off grade of 11.0 percent magnetite. The estimate is based on a total of 9,911 metres of diamond drilling in 73 holes. None of these holes were drilled by Strategic, but historic core, rejects and pulps have been reanalyzed and the historic database has been validated. The mineral resources are estimated using a three-dimensional block model with a nominal block size of 20 X 20 X 12.5 metres. Grade estimates for magnetite, vanadium, titanium and iron are based on geology, drill hole spacing and geostatistical analysis of drill hole sample data. The grade models have been validated using a combination of visual and statistical methods. Blocks in the model are estimated using five or more composite drill hole samples within a maximum average distance of 50m, 100m and 200m for the measured, indicated and inferred mineral resource categories respectively.

Mineral Resource Notes and Assumptions

(1) The mineral resource estimate has an effective date of September 14, 2020. (2) Mineral resources do not have demonstrated economic viability. (3) The mineral resources in this estimate were calculated with the Canadian Institute of Mining, Metallurgy and Petroleum (“CIM”), CIM Standards on Mineral Resources and Reserves, Definitions and Guidelines prepared by the CIM Standing Committee on Reserve Definitions. (4) Metal prices used: Pig Iron, US$350.00 per tonne and Ferrovanadium, US$30.00 per kilogram. (5) Base case cut-off grade for the estimate of the mineral resources is 11.0% magnetite. (6) It is reasonably expected that the majority of inferred mineral resources could be upgraded to indicated or measured mineral resources with continued exploration. (7) Strategic is not aware of any legal, political, environmental, or other risks that could materially affect the potential development of the mineral resources. (8) A 30-gram charge of agitated sample pulp “suspended” in water is separated magnetically as it passes through a rotating, inclined glass tube. The applied magnetic field causes magnetic minerals to stick to the tube walls. The weight percent of vanadium retained in the magnetic fraction is reported as VinMC (Vanadium in Magnetic Concentrate) and can be correlated with magnetically recovered vanadium grades in large scale magnetic separation plants. This work has indicated that the magnetite content could be upgraded by a factor of six. (9) Ti (titanium) and Fe (iron) grades and contained metal values are stated in recovered magnetite concentrate post upgrading.

Mining and Processing Facility

The PEA contemplates large-scale open pit mining using a 100% owner operated equipment fleet. Mine production and mill feed schedules were estimated from the phase resource tabulations using a declining cut-off grade strategy to maximize net present value for a processing rate of 10.4 ktpd. Pit limiting floating cone shells used to develop the mine plan were based on US$25.50/kg FeV80 price and US$340/t pig iron prices.

The ferrovanadium production process consists of a concentrator plant at the Mustavaara site and smelter / hydrometallurgical plants in Raahe. The concentrator plant process is based on crushing, two-stage grinding and multi-stage magnetic separation to produce iron/vanadium concentrate. The concentrate would then be transported approximately 250 km to Raahe using trucks.

Direct smelting and selective oxidation are used to bring vanadium to a suitable form (vanadium slag) to act as a feed material to the roast-leach process. Pig iron is produced as a co-product of the smelting process. A roast-leach process is used to produce vanadium pentoxide (V2O5) from vanadium slag. Vanadium pentoxide is then fed into an aluminothermic reduction to produce the final product, ferrovanadium (FeV80). Possible by-products include sodium sulphate, TiO2 slag and Ca-Al Slag.

 

Table 6: Processing Schedule

 

Table 7: Metallurgical Recoveries Summary

 

Tailings and Waste Rock Storage Facilities

The planned waste rock storage facility is located to the east of the open pit, partly at the north-east slope of the Mustavaara hill. The area was partly used for waste rock deposition during the previous mining operation. Due to the historic mining at Mustavaara, there is an existing tailings storage facility. The new deposition is planned on top of the existing deposition area.

Power Infrastructure and Water Requirements at the Mine Site

The total installed power of the concentration process main equipment has been estimated at 11.5 MW and total peak power including all processes is estimated at 18 MVA for 505,000 t/a concentrate production. The required electric power will be provided through connection to the local 110 kV power grid. The new 110 kV power line covers a distance of approximately 32 km and will be built to connect the mine site to an existing switchyard at the Posio municipality area. The power line route will follow the same path that was used during the former mining operations at Mustavaara. Water for processing would come from a raw water basin and from the Sirniönlampi lake.

Raahe Smelter Site

The proposed Raahe smelter site would be located at the Port of Raahe next to the SSAB steel plant. Both the regional and detailed land use planning processes for the smelter were completed in 2017. The surrounding infrastructure includes a harbor, railway line and the 110kV national grid. The area has a long history of steelmaking, which has created an extensive network of industrial services to Raahe.

Employment and Corporate Social Responsibility

During the construction period, 150-200 full-time employees are anticipated to be hired, which does not include outside contractors. The onsite construction workforce is estimated to vary during the construction period between 500 and 700 depending on the specific work being performed at the time. Over the 20-year mine life it is expected that the Project will employ 200 to 300 people.

Strategic is committed to earning and maintaining a robust social license to continue its Mustavaara mineral exploration and mine development operations in Finland. The Project has been designed to meet Finnish environmental regulations, international mining industry best management practices and appropriate international lending institution guidelines. As such, significant human and financial resources have been factored into the PEA to meet environmental obligations and social commitments.

Taxes Applied in the Economic Model

The PEA incorporates a 0.15% extraction royalty, a 20% Corporate Tax and several other local and municipal taxes. The total life of mine payments resulting from the royalty and taxes are €298M under the assumed commodity prices.

Qualified Persons

The scientific and technical information contained in this news release pertaining to the Project has been reviewed, verified and approved by the following Qualified Persons as defined by NI 43-101: Ville-Matti Seppä, EurGeol, (Mineral resources, process and Economic analysis) of AFRY Finland Oy, Eemeli Rantala, P.Geo (Environment) of AFRY Sweden Ab and Pekka Lovén, MAusIMM (Mine design) of PL Mineral Resources Services. All the Qualified Persons are independent of Strategic Resources Inc.

About Strategic Resources

Strategic Resources Inc. (TSXV:SR) is a Vancouver, Canada based mineral exploration and development company that is focused on vanadium projects in Finland and Peru. The Company is primarily focused on its flagship Mustavaara vanadium-iron-titanium project in Finland. The Company continues to evaluate new opportunities that are related to the electrification of the economy.

Further details are available on the Company’s website at https://strategic-res.com/.

To follow future news releases, please sign up at https://strategic-res.com/contact/.

STRATEGIC RESOURCES INC.

Signed: “Scott Hicks”

Scott Hicks, CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Information

Certain statements and information herein, including all statements that are not historical facts, contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to the mined and processed material estimates for the Project; the internal rate of return of the Project; the annual production of the Project; the net present value of the Project; the life of mine of the Project; the capital costs, operating costs and other costs and payments estimated for the Project and the proposed infrastructure for the Project (including how, when, where and by whom such infrastructure will be constructed or developed); projected metallurgical recoveries; the proposed level of employment at the Project; whether the Company will move the Project to a Pre-Feasibility stage; that the majority of inferred mineral resources could be upgraded to indicated or measured mineral resources with continued exploration; that the vanadium-iron concentrate that makes up the majority of the Project revenue will be trucked to Raahe and be processed into ferrovanadium and pig iron. Often, but not always, forward-looking statements or information can be identified by the use of words such as “will” or “projected” or variations of those words or statements that certain actions, events or results “will”, “could”, “are proposed to”, “are planned to”, “are expected to” or “are anticipated to” be taken, occur or be achieved.

With respect to forward-looking statements and information contained herein, the Company has made numerous assumptions including among other things, assumptions about general business and economic conditions, the prices of vanadium and pig iron, and anticipated costs and expenditures. The foregoing list of assumptions is not exhaustive.

Although management of the Company believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that a forward-looking statement or information herein will prove to be accurate. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These factors include, but are not limited to: risks associated with the business of the Company; business and economic conditions in the mining industry generally; the supply and demand for labour and other project inputs; changes in commodity prices; changes in interest and currency exchange rates; risks relating to inaccurate geological and engineering assumptions (including with respect to the tonnage, grade and recoverability of reserves and resources); risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters); risks relating to adverse weather conditions; political risk and social unrest; changes in general economic conditions or conditions in the financial markets; and other risk factors as detailed from time to time in the Company’s continuous disclosure documents filed with Canadian securities administrators. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

View original content to download multimedia:http://www.prnewswire.com/news-releases/strategic-resources-announces-mustavaara-pea-190m-after-tax-npv-8-with-a-20-year-mine-life-301282824.html

SOURCE Strategic Resources Inc.

PITTSBURGH, May 4, 2021 /PRNewswire/ —

/ Key Highlights

• 
  Fast Company’s 2021 World Changing Ideas Awards is focused on social good, seeking to elevate products and concepts that make the world better
• Ansys recognized as a finalist in the Software category; receives honorable mention in the Healthcare category

The winners of Fast Company‘s 2021 World Changing Ideas Awards were announced today, honoring the businesses, policies, projects, and concepts that are actively engaged and deeply committed to pursuing innovation when it comes to solving health and climate crises, social injustice, or economic inequality. Ansys (NASDAQ: ANSS) was recognized as a finalist in the Software category and received an honorable mention in the Healthcare category.

Ansys was recognized for generating a digital twin of the human heart. Ansys is working to revolutionize the treatment of potentially fatal heart arrythmias by creating patient-specific digital twins of human hearts that can be used to plan treatments and guide medical procedures. A key component of the digital twin is Ansys’ reduced order model (ROM), a simplified version of a high-fidelity model that makes computations faster with minimal sacrifice in predictive accuracy. While a simulation of a full model may consume hours, a ROM significantly speeds up the process, empowering a cardiologist to view results in real time.

This digital twin combines MRI imaging of the heart with a physics-based electrophysiological simulation, which will enable physicans to visualize a complete picture of the heart’s function, including the entire electric field that keeps it beating. Further development, testing and regulatory approvals are ongoing to achieve full-scale deployment of the digital twin into operating rooms.

A panel of eminent Fast Company editors and reporters selected winners and finalists from a pool of more than 4,000 entries across transportation, education, food, politics, technology, and more. Plus, several new categories were added, including Pandemic Response, Urban Design, and Architecture. The 2021 awards feature entries from across the globe, from Brazil to Denmark to Vietnam.

Showcasing some of the world’s most inventive entrepreneurs and companies tackling exigent global challenges, Fast Company‘s Summer 2021 issue (on newsstands May 10) highlights, among others, a lifesaving bassinet; the world’s largest carbon sink, thanks to carbon-eating concrete; 3D-printed schools; an at-home COVID-19 testing kit; a mobile voting app; and the world’s cleanest milk.

“Ansys’ industry-leading simulation solutions have the potential to transform patient-specific healthcare,” said Prith Banerjee, chief technology officer at Ansys. “In this case, through our work on the digital twin of a human heart — we are working to provide surgeons with valuable patient information, reduce the duration of ablation procedures and enhance fidelity.”

“There is no question our society and planet are facing deeply troubling times. So, it’s important to recognize organizations that are using their ingenuity, impact, design, scalability, and passion to solve these problems,” says Stephanie Mehta, editor-in-chief of Fast Company. “Our journalists, under the leadership of senior editor Morgan Clendaniel, have discovered some of the most groundbreaking projects that have launched since the start of 2020.”

/ About the World Changing Ideas Awards
World Changing Ideas is one of Fast Company‘s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose winners, finalists, and honorable mentions based on feasibility and the potential for impact. With the goals of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start working on solving the problems that affect us all.

/ About Ansys
If you’ve ever seen a rocket launch, flown on an airplane, driven a car, used a computer, touched a mobile device, crossed a bridge or put on wearable technology, chances are you’ve used a product where Ansys software played a critical role in its creation. Ansys is the global leader in engineering simulation. Through our strategy of Pervasive Engineering Simulation, we help the world’s most innovative companies deliver radically better products to their customers. By offering the best and broadest portfolio of engineering simulation software, we help them solve the most complex design challenges and create products limited only by imagination. Founded in 1970, Ansys is headquartered south of Pittsburgh, Pennsylvania, U.S.A. Visit www.ansys.com for more information.

Ansys and any and all ANSYS, Inc. brand, product, service and feature names, logos and slogans are registered trademarks or trademarks of ANSYS, Inc. or its subsidiaries in the United States or other countries. All other brand, product, service and feature names or trademarks are the property of their respective owners.

ANSS–T

/ Contacts

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ansys-named-finalist-in-fast-company-2021-world-changing-ideas-awards-301282787.html

SOURCE Ansys